Cauldron Ferm

Biomanufacturing uses living cells as programmable factories, where bio-engineered microbes convert simple inputs like sugars into valuable products. Cauldron’s key advantage is keeping these microbes in a highly productive steady state and running processes continuously for long periods. This increases output while significantly lowering production costs, helping bioproducts compete with conventional industrial alternatives.

Cauldron operates a 30,000-litre demonstration facility in Orange, NSW and works with partners to optimise and scale fermentation processes across sectors.

The industrial application of biotechnology is poised to reshape how products are sourced and secured. Estimates suggest up to 60% of inputs to the economy could be produced biologically. Cauldron’s technology makes this vision commercially viable by enabling production of bioproducts at the costs and volumes required for adoption.

• Companies pursuing bio-based solutions to industrial supply chain vulnerability
• Any bio-product that requires competitive costs and volumes for mainstream adoption

• $33M+ AUD raised in venture funding
• World Economic Forum 2025 Technology Pioneers list 
• Fast Company 2026 Most Innovative Companies list